HLA-B Allele Detection Kit for Sulfonamide Antiepileptic Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for accurately assessing and mitigating the risk of drug hypersensitivity reactions induced by antiepileptic sulfonamide derivatives, given the complexity of immune responses and numerous HLA alleles involved.
Innovation Solution
A method and test kit for detecting HLA-B*13:01, HLA-B*51:01, or HLA-B*51:02 alleles in subjects to identify the risk of developing hypersensitivity reactions, using oligonucleotides that specifically hybridize to these alleles, and administering appropriate treatments or alternative antiepileptic drugs without sulfonamide derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive HLA typing is performed to assess drug hypersensitivity risk, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent segments the comprehensive HLA typing process by focusing only on the specific HLA-B alleles (B*13:01, B*51:01, B*51:02) that are most strongly associated with sulfonamide-induced hypersensitivity. This selective approach maintains high measurement precision for the critical risk assessment while significantly reducing the complexity and cost compared to full HLA typing of all 300+ HLA-A and 600+ HLA-B alleles.
Solution Approach 2:
The patent extracts and isolates the most clinically relevant HLA alleles from the complex immune system background. By identifying and testing only the three specific alleles with strongest association to adverse reactions, the method removes unnecessary complexity while preserving the essential risk assessment capability.
2Measurement precision
If multiple HLA alleles are tested to improve risk assessment, then measurement precision is improved, but loss of time increases
Solution Approach 1:
The patent divides the extensive HLA typing task into a focused set of three specific alleles (B*13:01, B*51:01, B*51:02) that account for the majority of sulfonamide-induced hypersensitivity cases. This segmentation reduces testing time significantly while maintaining high precision, as these three alleles are tested instead of hundreds of HLA alleles.
Solution Approach 2:
The patent performs preliminary identification of the critical HLA alleles through extensive research and validation before implementing the test. This preliminary work allows the clinical test to be rapid and focused, eliminating the need for time-consuming comprehensive typing while ensuring accurate risk assessment.
3Measurement precision
If comprehensive immune mechanism analysis is performed, then measurement precision is improved, but ease of operation deteriorates
Solution Approach 1:
The patent extracts the most operationally simple and clinically relevant HLA alleles from the complex immune system. By focusing on three specific alleles with strong association to hypersensitivity, the method maintains high measurement precision while making the testing procedure simple and easy to operate, avoiding the complexity of analyzing all 300+ HLA-A and 600+ HLA-B alleles.
Solution Approach 2:
The patent uses HLA-B alleles as intermediary markers to assess drug hypersensitivity risk. These HLA alleles serve as accessible, easy-to-test intermediaries that reflect the complex immune mechanism without requiring direct analysis of the complex immune response itself, thus maintaining simplicity while achieving high precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effectively assesses the risk of severe cutaneous adverse reactions and reduces the incidence of drug hypersensitivity reactions by identifying high-risk alleles and providing targeted treatment strategies.
Implementation Method 1
the presence of HLA-B*13:01, HLA-B*51:01 or HLA-B*51:02 allele is determined by an oligonucleotide that specifically hybridizes to the allele
Data Source
AI summary
The present invention provides a method for assessing the risk of drug hypersensitivity reaction caused by an antiepileptic drug with a sulfonamide derivative in a subject in need of such an assessment, comprising the step of detecting the presence of HLA-B alleles in the sample obtained from the subject, wherein the presence of the allele indicates that the subject has an increased risk of developing drug hypersensitivity reaction caused by the antiepileptic drug with the sulfonamide derivative. The present invention also provides a method for treating or reducing the incidence of such drug hypersensitivity reaction. Also provided are a test kit for assessing the risk of a patient developing drug hypersensitivity reaction caused by an antiepileptic drug with a sulfonamide derivative, comprising a reagent for determining specific HLA alleles, and use of the test kit in assessing the risk of a patient developing drug hypersensitivity reaction caused by an antiepileptic drug with a sulfonamide derivative.